

Product datasheet for TL314101V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

CD200 Human shRNA Lentiviral Particle (Locus ID 4345)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: CD200 Human shRNA Lentiviral Particle (Locus ID 4345)

Locus ID: 4345

Synonyms: MOX1; MOX2; MRC; OX-2

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

CD200 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001004196, NM 001004197, NM 001318826, NM 001318828, NM 001318830,

NM 005944, NM 005944.2, NM 005944.3, NM 005944.4, NM 005944.6, NM 001004196.1, NM 001004196.2, NM 001004196.3, NM 001004197.1, BC031103, BC031103.1, BC022522,

NM 001365851, NM 001365852, NM 001365853, NM 001365854, NR 158642,

NM 001365855

UniProt ID: P41217

Summary: This gene encodes a type I membrane glycoprotein containing two extracellular

immunoglobulin domains, a transmembrane and a cytoplasmic domain. This gene is

expressed by various cell types, including B cells, a subset of T cells, thymocytes, endothelial cells, and neurons. The encoded protein plays an important role in immunosuppression and regulation of anti-tumor activity. Alternative splicing results in multiple transcript variants

encoding different isoforms. [provided by RefSeq, Jan 2016]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).